Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights, Trends and Forecast (2019-2028)
The global Non-Alcoholic Steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs.
By: Koncept Analytics
The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market in coming years, with considerable market share. The need for definitive NASH treatment would lead to strong market penetration of the therapeutic drugs during the forecasted period.
The fastest growing regional market would be the U.S., due to the increasing prevalence of NASH, along with forthcoming launches of various NASH therapeutic drugs. Moreover, Europe is also expected to hold a significant share in the global NASH therapeutics market, owing to the growing awareness amongst the inhabitants, regarding NASH diagnosis and treatment methods.
Scope of the report:
• The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs sub markets.
• The major regional markets (the U.S. and Europe) have been analyzed.
• The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
• The competitive landscape of the market, along with the company profiles of leading players (Bristol Myers Squibb, Gilead Sciences, Allergan Plc. (Tobira), Intercept Pharmaceuticals, Galmed Pharmaceuticals and Genfit SA) are also presented in detail.
For more Information:
(Business Development Manager)
FFCS-36, Ansal Plaza
U.P - 201010
Mail ID – firstname.lastname@example.org